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Abstract
Background: Alzheimer’s disease results from a neurodegenerative process that starts well before the diagnosis can
be made. New prognostic or diagnostic markers enabling early intervention into the disease process would be
highly valuable. Environmental and lifestyle factors largely modulate the disease risk and may influence the
pathogenesis through epigenetic mechanisms, such as DNA methylation. As environmental and lifestyle factors
may affect multiple tissues of the body, we hypothesized that the disease-associated DNA methylation signatures
are detectable in the peripheral blood of discordant twin pairs.
Results: Comparison of 23 disease discordant Finnish twin pairs with reduced representation bisulfite sequencing
revealed peripheral blood DNA methylation differences in 11 genomic regions with at least 15.0% median
methylation difference and FDR adjusted p value ≤ 0.05. Several of the affected genes are primarily associated with
neuronal functions and pathologies and do not display disease-associated differences in gene expression in blood.
The DNA methylation mark in ADARB2 gene was found to be differentially methylated also in the anterior
hippocampus, including entorhinal cortex, of non-twin cases and controls. Targeted bisulfite pyrosequencing of the
DNA methylation mark in ADARB2 gene in 62 Finnish and Swedish twin pairs revealed that, in addition to the
disease status, DNA methylation of this region is influenced by gender, age, zygosity, APOE genotype, and smoking.
Further analysis of 120 Swedish twin pairs indicated that this specific DNA methylation mark is not predictive for
Alzheimer’s disease and becomes differentially methylated after disease onset.
Conclusions: DNA methylation differences can be detected in the peripheral blood of twin pairs discordant for
Alzheimer’s disease. These DNA methylation signatures may have value as disease markers and provide insights into
the molecular mechanisms of pathogenesis. We found no evidence that the DNA methylation marks would be
associated with gene expression in blood. Further studies are needed to elucidate the potential importance of the
associated genes in neuronal functions and to validate the prognostic or diagnostic value of the individual marks or
marker panels.
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Introduction
Alzheimer’s disease (AD) is an aging-associated neuro-
degenerative disorder and the most common cause of
dementia. The molecular mechanisms of AD are not
known in detail. The disease is characterized by accumu-
lation of beta-amyloid plaques and hyperphosphorylated
tau protein in the brain tissue. The pathological changes
can start decades before the first clinical symptoms ap-
pear [1–3]. In the early-onset form of AD, which ac-
counts for approximately 2–10% of the cases, the
symptoms can start already before age of 30 years. In 5–
10% of the early onset cases, the disease is caused by
autosomal dominant mutations in the genes APP,
PSEN1, and/or PSEN2 [1, 4]. The majority of AD cases
are of the late-onset form, which typically manifests after
65 years of age [1, 4]. Based on twin studies, the esti-
mated heritability of the disease exceeds 50% [5]. Gen-
etic association with apolipoprotein E (APOE) epsilon 4
(ε4) allele is common in both early- and late-onset form.
Furthermore, genome-wide association studies have
identified over 20 additional variants each contributing
less than 1% to the heritability of liability. Together with
APOE ε4, these known variants explain approximately
29% of the heritability [4, 6–8] leaving a large fraction
unexplained.
In addition to genetic factors, the morbidity of AD is
influenced by modifiable lifestyle factors, such as phys-
ical activity and cognitive ability, nutrition, alcohol use,
and smoking [1, 9]. These factors may influence the dis-
ease process through epigenetic mechanisms, such as
DNA methylation, by causing changes detectable in vari-
ous tissues. Such changes may provide insights into the
molecular mechanisms of the disease and have potential
as informative biomarkers. DNA methylation marks as-
sociated with AD have been discovered in several brain
regions [10–14]. Whether similar marks exist in periph-
eral blood is still unclear [15]. The question is compli-
cated by the fact that methylation levels at CpG sites
associated with the disease may be driven by genetic var-
iants. Within-pair comparison of disease-discordant
monozygotic (MZ) twin pairs with, in practice, identical
genomes, the same age and sex, and who share many
intrauterine and early-life environmental factors pro-
vides a powerful approach for detection of the disease-
associated methylation sites [16]. Dizygotic (DZ) disease-
discordant twin pairs also provide improved sensitivity
to the analyses as they share on average 50% of their
genome and are of the same age and matched for pre-
natal and shared rearing environmental factors.
Modern technologies, such as positron emission tom-
ography (PET), enable monitoring of the disease status
in the brains of living subjects and are already utilized in
diagnostics together with clinical examination and bio-
markers to identify the individuals with first symptoms
[9, 17, 18]. However, novel high-throughput methods
enabling early detection and large scale monitoring of
the disease status would be highly valuable. The aim of
this study was to identify epigenetic marks associated
with late-onset AD in peripheral blood by comparing
DNA methylation profiles of the disease-discordant twin
pairs and to examine overlap in brain tissue. To evaluate
potential as prognostic or diagnostic marker, one of the
most interesting loci was selected for validation in ex-
tended twin cohorts from Finland and Sweden.
Results
Twin pairs discordant for Alzheimer’s disease have similar
genetic risk load for the disease
Before identification of the epigenetic marks, the genetic
risk load of the twin pairs for Alzheimer’s disease was
characterized. To measure the genetic risk load for AD
in the Finnish study subjects, we analyzed the APOE ge-
notypes and 21 loci previously associated with AD as a
risk or protective variants (Table 2, Additional file 1) [4,
6]. In this analysis, we included 9 full MZ and 12 full DZ
AD-discordant twin pairs, 9 unrelated controls, and 18
unrelated cases (Table 1). Monozygotic co-twins were
confirmed to have identical single nucleotide poly-
morphism (SNP) profiles. All dizygotic co-twins were
identical for the DSG2, CASS4, and SORL1 alleles but
carried differences in 2–10 other variants. Most of the
twin pairs (17 of 23 pairs) had APOE ε3ε3 genotype.
Standardized GRS were calculated for the study groups
based on the 21 loci previously associated with AD
(Table 2). According to the generalized linear regression
analysis, the GRS was not associated with the disease
status (Wald test z value < 1, Pr(>[z]) > 0.5).
Blood DNA methylation marks associated with
Alzheimer’s disease in the Finnish twin cohort
Our first research question was whether DNA methyla-
tion marks associated with AD can be detected in the
peripheral blood of disease discordant twin pairs. The
null hypothesis was that peripheral blood DNA methyla-
tion is not associated with the disease status. To address
this hypothesis, we first identified the within-pair methy-
lation differences associated with AD in 11 MZ twin
pairs with reduced representation bisulfite sequencing
(RRBS) as described in the “Methods” section (Table 1).
This comparison revealed 427 CpG sites with increased
and 474 sites with decreased methylation in AD cases
when using cut off values of at least 15.0% median
methylation difference and Benjamin-Hochberg false dis-
covery rate (B-H FDR) adjusted p value ≤ 0.05 (Fig. 1a,
Additional file 2a). Similarly, CpG methylome differ-
ences were then identified in 12 DZ twin pairs discord-
ant for AD. This comparison revealed 1337 sites with
increased and 764 sites with decreased methylation in
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AD cases (Fig. 1b, Additional file 2b). We then examined
the overlap of differentially methylated CpG sites de-
tected in both MZ and DZ within-pair comparisons.
This revealed 11 common sites with consistent methyla-
tion difference present in both zygosity groups (adjusted
p value ≤ 0.05), (Fig. 1c, d, Additional file 2c and Add-
itional file 3). The genes nearest or overlapping with
these regions included DEFA1 (intron), TSNARE1 (in-
tron), DEAF1 (intron), ARAP2 (− 2,197,329 bp from
TSS), CNPY1 (+ 764 bp from TSS), ADARB2 (exon),
ARHGAP8 (intron), GTF3C2 (− 1157 bp from TSS),
ACTA1 (+ 29543 bp from TSS), SEMA5A (+ 694751 bp
from TSS), and CLIP2 (+ 121538 bp from TSS). No
methylation differences were detected in the mitochon-
drial DNA or X chromosome with the chosen filtering
criteria. In summary, DNA methylation changes in 11
genomic regions were found to be associated with AD in
peripheral blood of AD-discordant Finnish twin pairs.
These regions are henceforth referred to as AD-associ-
ated loci in blood. Based on these results, we could re-
ject the first null hypothesis for the 11 CpG sites.
Overlap of DNA methylation marks associated with
Alzheimer’s disease in the anterior hippocampus and
peripheral blood
Our second research question was whether the DNA
methylation marks associated with AD in peripheral
blood are also detectable in brain tissue. Our null hy-
pothesis was that DNA methylation marks associated
with AD in the anterior hippocampus, including the en-
torhinal cortex, do not overlap with those detected in
peripheral blood. Anterior hippocampus, including ento-
rhinal cortex, was selected for analysis, as these brain re-
gions are crucial for memory formation and learning.
Both regions were analyzed together as they were not
available separately from the biobank. To test the hy-
pothesis, the DNA methylation was profiled with the
RRBS from postmortem tissue sections collected from
six cases with AD and six controls (Table 1). Two cases
were excluded from the final analysis as one was identi-
fied to be an outlier in the principal component analysis,
and according to the neuropathological examination,
one sample was from amygdala. Comparison of cases
and controls with MethylKit R package revealed in-
creased methylation at 114 sites and decreased methyla-
tion at 87 genomic sites among AD cases (at least 15.0%
methylation difference, SLIM adjusted q value ≤ 0.05),
overlapping or closest to the 176 gene identifiers, in the
anterior hippocampus (Fig. 2a). These sites are hence-
forth referred to as AD-associated loci in the brain.
Comparison of the gene identifiers closest to the AD-as-
sociated loci in the brain to those detected in blood re-
vealed one overlapping gene ADARB2 (Fig. 2b). In the
gene ADARB2, the differentially methylated sites in
Table 1 Characteristics of the samples utilized in the study
Controls Cases
Study and sample type No of subjects (male/female) Age range
(years)
No of subjects (male/female) Age range (years)
Finnish cohort (n = 97)
Peripheral blood (n = 93)
ADDa MZ twin pairs 12/9 67–86 12/9 67–86
ADD DZ twin pairs 6/6 70–72 6/6 70–72
Unrelated individuals 1/8 61–77 9/9 70–86
Peripheral blood mononuclear cells (n = 4)
MZ twin pairs discordant for episodic memory 2/0 76 2/0 76
Swedish cohort (n = 298)
Peripheral blood (n = 298)
ADD MZ twin pairs 5/5 62–83 5/5 63-83
ADD DZ twin pairs 11/8 63–84 11/8 63–84
Incidentb ADD MZ twin pairs 15/23 62–85 15/23 62–85
Incident ADD DZ twin pairs 33/49 53–88 33/49 53–88
NIH NeuroBioBank (n = 12)
Anterior hippocampus with entorhinal cortex (n = 12)
Unrelated individuals 4/2 56–89 4/2 57–90
Total (n = 407) 89/110 53–90 97/111 53–90
aAlzheimer’s disease-discordant
bSample collected 0.5–18.5 years before disease onset
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blood and hippocampus were localized within the same
region chr10:1404752-1405717 in exon 3, in the proxim-
ity of the exon 3-intron junction. Therefore, the second
null hypothesis was rejected.
We also examined the correlation of AD-associated
loci in blood with the brain tissue in the publicly avail-
able Illumina 450K data by using the online tool https://
epigenetics.essex.ac.uk/bloodbrain/. Only two of the AD-
associated loci in blood identified in this study are de-
tected by Illumina 450K arrays, including probe
cg26376030 in DEAF1 gene and cg22909083 in DEFA1B
gene locus. The peripheral blood DNA methylation of
probe cg22909083 had high correlation (> 0.95, p < 0.05)
with all the four regions of brain available in the data-
base, including prefrontal cortex, entorhinal cortex, su-
perior temporal gyrus, and cerebellum. The probe
cg26376030 had modest correlation (> 0.26, p < 0.05)
with prefrontal cortex, entorhinal cortex, and superior
temporal gyrus (Additional file 4).
Gene expression levels in whole blood and individual
lymphocytes
Our third research question was whether the genes clos-
est to DNA methylation marks in the blood are also as-
sociated with differences in gene expression in
peripheral blood from AD cases compared to controls.
Our null hypothesis was that the expression of the genes
closest to the AD-associated loci in blood is not associ-
ated with AD. To address this hypothesis, expression of
the 11 genes overlapping or closest to the AD-associated
loci (Fig. 1d, Additional file 2c) were examined in the
data from whole blood (GSE63061, Europeans) of 122
controls and 121 cases with AD [19] available at the
GEO database. Expression of 9 genes was detected; how-
ever, there were no differences between AD cases and
controls (Additional file 5). Expression of these genes
was further examined in individual peripheral blood
mononuclear cells (PBMCs) of two twin pairs discordant
for episodic memory, one of which were also discordant
Table 2 Genetic risk load for Alzheimer’s disease in the Finnish twin pairs and unrelated individuals
Minor allele frequencies
SNP Minor/
major
allele
Closest
gene
Log-OR (p≤
1.0×10−4)a
Meta-
analysisa
MZ twin
pairs (n = 9)
DZ twin
controls (n =
12)
DZ twin
cases (n =
12)
Unrelated
controls (n = 9)
Unrelated
cases (n = 18)
All
(n =
62)
rs10498633 G/T SLC24A4-
RIN3
− 0.094 0.22 0.22 0.21 0.17 0.17 0.17 0.18
rs10792832 G/A PICALM − 0.140 0.36 0.44 0.5 0.58 0.39 0.42 0.47
rs10838725 T/C CELF1 0.079 0.32 0.28 0.29 0.29 0.33 0.31 0.3
rs10948363 A/G CD2AP 0.095 0.27 0.22 0.08 0 0.22 0.11 0.12
rs11218343 T/C SORL1 − 0.262 0.04 0.00 0 0 0 0 0
rs11771145 G/A EPHA1 − 0.102 0.34 0.28 0.42 0.42 0.33 0.22 0.32
rs1476679 T/C ZCWPW1 − 0.089 0.29 0.44 0.33 0.37 0.33 0.39 0.37
rs17125944 T/C FERMT2 0.132 0.09 0.11 0.08 0.17 0.22 0.11 0.13
rs190982 A/G MEF2C − 0.076 0.41 0.44 0.33 0.29 0.33 0.28 0.32
rs2718058 A/G NME8 − 0.077 0.37 0.33 0.17 0.29 0.44 0.19 0.27
rs28834970 T/C PTK2B 0.100 0.37 0.44 0.29 0.21 0.39 0.31 0.32
rs35349669 C/T INPP5D 0.076 0.49 0.50 0.58 0.62 0.11 0.53 0.49
rs3865444 C/A CD33 − 0.067 0.31 0.11 0.42 0.33 0.33 0.36 0.32
rs4147929 G/A ABCA7 0.143 0.19 0.06 0.17 0.12 0.11 0.14 0.12
rs6656401 G/A CR1 0.167 0.20 0.22 0.42 0.33 0.33 0.22 0.3
rs6733839 C/T BIN1 0.197 0.41 0.33 0.54 0.37 0.56 0.36 0.42
rs7274581 T/C CASS4 − 0.132 0.08 0 0 0 0 0 0
rs8093731 C/T DSG2 − 0.316 0.02 0 0 0 0 0 0
rs9271192 A/C HLA-
DRB5/-
DRB1
0.108 0.28 0.33 0.29 0.42 0.33 0.56 0.41
rs9331896 T/C CLU − 0.146 0.38 0.22 0.58 0.42 0.28 0.5 0.42
rs983392
GRSb
A/G MS4A6A − 0.108 0.40 0.39
− 0.16
0.42
− 0.27
0.33
− 0.39
0.61
− 0.28
0.39
− 0.03
0.42
− 0.36
aFrom Lambert et al.
bMedian standardized genetic risk score
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Fig. 1 Peripheral blood CpG methylation differences in Finnish twin pairs discordant for Alzheimer’s disease. Peripheral blood CpG methylomes of
11 monozygotic (MZ) and 12 dizygotic (DZ) Finnish twin pairs discordant for Alzheimer’s disease (AD) were profiled with reduced representation
bisulfite sequencing. Differentially methylated sites associated with AD in autosomes were identified using RADMeth algorithm and ± 15.0%
average methylation difference and B-H FDR adjusted p value cut off 0.05 in a MZ and b DZ twin pairs separately. c Differentially methylated sites
detected in both MZ and DZ twin pairs were extracted to identify overlaps between the AD-associated sites detected in both groups
(Additional file 2). d Combined median methylation difference and adjusted p value (adj. pval) distribution of these 11 regions associated with AD
in both MZ and DZ twin pairs is illustrated. The size of the dot indicates the percentage of the twin pairs, which had the required ≥ 10×
coverage in the region. The closest or overlapping gene is indicated for the selected differentially methylated regions
Fig. 2 Differentially methylated sites associated with Alzheimer’s disease in the anterior hippocampus. DNA methylation profiles of anterior
hippocampus samples of 10 non-twin subjects, including six references and four with Alzheimer’s disease (AD), were examined with reduced
representation bisulfite sequencing. The samples were from NIH NeuroBioBank. a Differentially methylated sites (201 CpGs) were identified with
MethylKit package in R by using a minimum of 15% methylation difference and q value below 0.05 as filtering cutoff (Additional file 2d). The 201
differentially methylated CpG sites overlapped or were closest to 176 genes (AD-associated genes in the brain). Examples of the genes are
shown. b Overlap of genes with AD-associated DNA methylation marks in both peripheral blood and anterior hippocampus of the brain
Konki et al. Clinical Epigenetics          (2019) 11:130 Page 5 of 12
for mild AD. The proportions of blood cell types ex-
pressing these genes were similar between the co-twins
and no major differences were detected in the expression
of the genes within the twin pairs (Additional files 6 and
7). In conclusion, analysis of blood did not provide evi-
dence that the genes would display major disease associ-
ated functional significance in the PBMC populations.
Based on our data, we could not reject the third null
hypothesis.
Targeted validation of disease-associated methylation
changes in ADARB2 gene in Finnish and Swedish twin
pairs discordant for AD
Our fourth research question was whether the DNA
methylation mark in the ADARB2 gene can be validated
with targeted bisulfite pyrosequencing in an extended
cohort including an independent twin cohort from
Sweden. The null hypothesis was that the DNA methyla-
tion mark in ADARB2 is not associated with AD in an
extended cohort. To address this hypothesis, the CpG
methylation of the region (chr10:1,405,405-366) in
ADARB2 gene was analyzed with targeted bisulfite pyro-
sequencing in 62 of AD discordant twin pairs including
33 Finnish and 29 Swedish twin pairs. Association of the
CpG methylation with AD was analyzed using linear
mixed effects model (lme) [20]. Initially, several models
were compared with ANOVA including or excluding zy-
gosity, age, and gender as fixed effects and twin pair
identification number nested with genomic position and
country of origin as random effects. The model with
lowest AIC value was selected as the final model: methy-
lation level (%) ~ disease status + zygosity + age + gender
+ diseases status × zygosity + disease status × age + dis-
ease status × gender + (1 | twin pair identification num-
ber/genomic position). Influence of APOE genotype
(ε34/ε44 and ε33) was examined separately, including
disease status and gender as fixed effects, to ensure suffi-
cient number of observations in each subgroup. The in-
fluence of APOE genotype was examined because it is a
well-known risk factor for AD and can influence the
progression and severity of the disease, which in turn
may be reflected in the state of the DNA methylation
marks associated with the disease. Increased CpG
methylation level of the region chr10:1,405,405-366 was
validated to be associated with AD (Wald t value 4.68)
and was influenced by interaction with gender, zygosity,
and age. Separate examination by sex revealed that the
CpG methylation level was increased in male cases
(Wald t value 6.10) (Fig. 3a, Additional file 8). The
methylation difference of the region was higher in DZ
than MZ twin pairs (estimate 7.67%, standard error (SE)
1.44, Wald t value 5.34) (Fig. 3b), indicating that the as-
sociation is influenced by genetic factors. In addition, in
males the CpG methylation difference between
discordant twin pairs increased with age (estimate 1.00%
per year, SE 0.15, t value 6.43) (Fig. 3c). Interestingly, in
females, the CpG methylation was increased in cases
with APOE ε34/ε44 genotype (Wald t value 3.44); how-
ever, it was not increased in cases with the ε33 genotype
(Wald t value − 1.67) (Fig. 3d). In male cases, the CpG
methylation level was higher among cases than controls
in both APOE genotype groups (Wald t value > 3.83),
and in male cases, the level in APOE ε34/ε44 group was
higher in comparison to the male cases with ε33 geno-
type (Wald t value 4.59). Of note, visual examination re-
vealed that also the male cases with ε33 genotype had
polarized into high and low/intermediate CpG methyla-
tion level groups (Fig. 3e).
Next, we determined whether the association of the
methylation mark with AD is attenuated and if also
smoking history is included as a fix effect and inter-
action term in the linear mixed effects model. Smoking
data was available for 60 twin pairs, including 49 current
or past smokers and 15 smoking discordant pairs. The
association of the methylation mark with the disease sta-
tus was not attenuated when smoking was included in
the analysis (estimate 64.51%, SE 9.23, and Wald t value
6.99). However, the smoking did interact with the dis-
ease (estimate 8.10%, SE 1.43, and Wald t value 5.68).
The median methylation level of the mark was higher in
those cases who were current or past smokers in com-
parison to controls and cases who had never smoked or
controls who were current or past smokers (Add-
itional file 9). The association with the disease remained
significant also in the model with adjustment for APOE
genotype (estimate 35.41%, SE 9.41, and Wald t = 3.76).
In conclusion, our findings from targeted analysis con-
firm the association of CpG methylation in region chr10:
1,405,405-366 with AD and the methylation is influ-
enced by gender, age, zygosity, APOE genotype, and
smoking. Thus, based on our results, the fourth null hy-
pothesis was rejected.
CpG methylation status of region chr10:1,405,405-366 in
ADARB2 gene does not predict the disease outcome
Our fifth and last research question was whether the
DNA methylation mark in ADARB2 is predictive for
AD. The null hypothesis was that the DNA methylation
mark in ADARB2 gene is not associated with incident
AD. To address this hypothesis, the methylation level in
region chr10:1,405,405-366 was analyzed with targeted
bisulfite sequencing and Cox mixed effects model was
used to examine the association of CpG methylation
with disease outcome in samples collected 0.5–18.5 years
before disease onset from 120 discordant twin pairs from
Sweden. The gender and age at blood draw were in-
cluded as fixed effects in the analysis and relatedness
nested with genomic position as a random effect.
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According to the results, the disease outcome was not
associated with the DNA methylation level of the region
before disease onset (hazard ratio = 1.00, 95% confidence
interval = 1.00–1.00, p = 0.63). Thus, the fifth null hy-
pothesis was not rejected (Fig. 3f).
Discussion
Our results show that differences in DNA methylation
associated with AD can be detected in the peripheral
blood in at least 11 genomic regions. Although the func-
tional importance of the affected regions in transcrip-
tional regulation requires further studies, our results
suggest that the DNA methylation marks are not
associated with gene expression in peripheral blood. Sev-
eral of these genes have been previously linked to neuro-
logical functions or pathologies. Among the most
interesting findings was the AD-associated methylation
signature in the exon 3 of ADARB2 gene, which was de-
tected in both peripheral blood and anterior hippocam-
pus in brain tissue. Based on previous studies,
expression of ADARB2 is brain specific; however, its
function has not been fully characterized. ADARB2 may
have a function in the inhibition of RNA editing by
ADAR1 and ADAR2 proteins [21–23]. Importantly, a re-
cent study showed that mice lacking the corresponding
exon 3 of ADARB2 gene display impaired hippocampus-
Fig. 3 The DNA methylation status of the ADARB2 gene is associated with Alzheimer’s disease. The DNA methylation level of region
chr10:1,405,405-366 in exon 3 of ADARB2 gene was measured with targeted pyrosequencing in blood DNA samples collected from Finnish (33
pairs) and Swedish (29 pairs) twin pairs discordant for Alzheimer’s disease (AD). The association of the disease status with DNA methylation was
examined with linear mixed effects model including gender, zygosity, age, and interaction terms as fixed effects and twin pair information nested
with genomic position as a random effect. The country of origin was not associated with the CpG methylation level and was excluded from the
final models. a The CpG methylation level in male and female controls (ctrl) and cases. Wald t value for disease association including both
genders is 4.68, for males 6.10, and for females 1.17. b Influence of zygosity of CpG methylation difference between twin pairs discordant for AD.
c Influence of age on the CpG methylation difference between AD discordant twin pairs. Influence of APOE genotype on the CpG methylation
level was examined separately including only gender as a covariate. Only group ε33 and combined groups ε34/44 were included in the statistical
analysis. The CpG methylation levels for d female and e male ctrls and cases in different APOE groups. f CpG methylation difference in AD
discordant twin pairs before onset of the diseases (not predictive for disease outcome based on Cox mixed effects model). In b–f, the
representative data for CpG site 6 in the region is shown, and in a, c, and f, the lines are the smoothed conditional means with 0.95 confidence
intervals area
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dependent memory formation, learning, and regulation
of genes implicated in synaptic functions [24]. Consist-
ently, a variant in ADARB2 gene has been associated
with accelerated cognitive decline after conversion from
mild cognitive impairment (MCI) to AD [25]. With tar-
geted validation including independent twin pairs dis-
cordant for AD from both Finnish and Swedish cohorts,
we further found that the methylation level in ADARB2
was associated with APOE genotype, age, gender, and
smoking which all also influence risk of AD. Although
these results together suggest potential importance of
ADARB2 in the molecular pathology of AD, the high in-
ter-individual variance and relatively small within-pair
differences in blood suggest that methylation at this re-
gion alone is unlikely to have value as a diagnostic
marker. Furthermore, CpG methylation in ADARB2 was
not predictive for AD when measured before disease
onset.
Similarly to ADARB2, several of the differentially
methylated regions in blood overlapped or were closest
to genes that are highly expressed in the brain or have
been previously linked to neuronal functions or patholo-
gies, such as neurogenesis, synaptic function, cognitive
decline, intellectual disability, social interaction, schizo-
phrenia, and Parkinson’s and Alzheimer’s diseases [24,
26–31]. For example, increased levels of alpha defensins
(encoded by DEFA1) have been reported in the CSF of
patients with AD [29], whereas mutations in DEAF1
gene can cause severe intellectual disability and behav-
ioral problems. Conditional knockout of Deaf1 gene in
mouse model leads to a phenotype with impaired mem-
ory and increased anxiety [26]. TSNARE1 gene has been
previously associated with schizophrenia and rate of cog-
nitive decline in late MCI [32–34].
Why DNA methylation marks associated with neuro-
degenerative disease can be detected in the blood is not
fully clear. One potential explanation is that these marks
are caused by environmental or lifestyle factors, which
affect the methylation status of DNA also in peripheral
blood; however, the influence on the disease process
manifests only in the specific tissues where the affected
genes are functionally active or important. Nonetheless,
potential importance of these genes in the neuronal
functions and disease process remains to be elucidated.
Further studies are also needed to elucidate whether
combinations of differentially methylated regions in mul-
tiple AD-associated loci would increase sensitivity in dis-
tinguishing AD cases from cognitively preserved
controls and to evaluate the value of these changes as
predictive disease markers.
Previously, two independent large-scale studies on dif-
ferent regions of the brain have found DNA methylation
marks in the ANK1 and RHBDF2 genes to be associated
with AD [11, 12]. Both studies utilized Illumina 450K
arrays. These regions were not captured by the RRBS
method utilized in our study. Vice versa, the differen-
tially methylated region in ADARB2 gene found in this
study is not covered by the probes present in 450K
array.
A limitation in our study is that no adjustment for
smoking was performed in the RRBS analysis due to the
small number of samples for this variable available in
the discovery cohort. To our knowledge, the genes near-
est to the differentially methylated sites in peripheral
blood have not been previously associated with smoking,
suggesting that the results were not confounded by this
factor. Another limitation is that the analysis was carried
out by using whole blood and cell type heterogeneity
can potentially confound the results. The adjustment of
the RRBS results with the Bacon method is expected to
correct for potential bias caused by cell type
heterogeneity.
Conclusions
Our results show that DNA methylation differences can
be detected in the peripheral blood of twin pairs dis-
cordant for Alzheimer’s disease. These DNA methylation
signatures may have value as disease marker candidates
and may provide insights into the molecular mecha-
nisms of pathogenesis. Our results suggest that the DNA
methylation marks do not associate with gene expression
in blood. Further studies are needed to elucidate the
functional importance of the affected genes and to valid-
ate the prognostic or diagnostic value of the individual
marks or marker panels.
Methods
Study participants and samples
A total of 395 peripheral blood samples from Finnish
and Swedish cohorts and 12 brain samples from NIH
NeuroBioBank were analyzed in this study (Table 1). In
more detail, the older Finnish twin cohort [35, 36] of
2483 individuals, born 1922–1937, had been previously
screened for cognitive functions by phone interview [37],
and the discordant twin pairs were invited to neuro-
psychological testing, brain magnetic resonance imaging,
PET amyloid imaging [18, 38–41], and collection of
EDTA blood samples. Based on the overall evaluation, a
diagnosis of AD was made (29 pairs). The controls were
not required to have negative PET amyloid imaging. In
addition to the original cohort, four twin pairs born in
1915–1950 were included in the study. Furthermore, BD
Vacutainer® CPT™ samples were collected from two MZ
twin pairs (age 76 years) discordant for episodic memory,
where one pair was also discordant for mild AD. These
two twin pairs were from a younger Finnish twin cohort
(born in 1938–1944). The blood DNA samples from
Swedish twin pairs (149 pairs), born 1907–1953, were
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from the Swedish Twin Registry [42] and had been col-
lected before (120 pairs) or after (29 pairs) the onset of
the disease. The participants originated from three sub-
studies of aging within the Swedish Twin Registry [42],
namely the Swedish Adoption/Twin Study of Aging
(SATSA) [43], the Study of Dementia in Swedish Twins
(HARMONY) [44], and TwinGene [42]. Disease infor-
mation was available through linkage to nationwide
health registers for all Swedish twins, and in addition,
AD was clinically evaluated as part of the SATSA and
HARMONY study [45]. Furthermore, our study material
included fresh frozen post-mortem brain tissue from an-
terior hippocampus, including dentate gyrus and ento-
rhinal cortex. The samples had been collected from 12
adults (57–90 years), including six patients with AD and
six non-demented controls. Five of the individuals were
white and seven had unknown ethnic origin.
Nucleic acid extractions
The DNA was extracted from EDTA blood with Qiagen
QIAamp DNA Blood kit and from fresh frozen tissue
with QIAamp DNA Micro kit. Qubit 3.0 dsDNA HS
Assay, Thermo Scientific NanoDrop 2000, and Fragment
Analyzer HS Genomic DNA assay (Advanced Analytical)
were used for the quality analysis and quantitation.
Targeted genotyping and variant data analysis
Genotyping of APOE alleles and 21 SNPs previously as-
sociated with AD [6] (Table 2) was performed with Illu-
mina TruSeq Custom Amplicon assay and sequencing
(500 cycles) with Illumina MiSeq. Illumina BaseSpace
was used for variant analysis. Genetic risk scores were
calculated based on 21 genetic variants by summing up
the number of risk or protective alleles, weighted by the
effect size from the stage 1 and 2 meta-analyses in a gen-
ome-wide association study of AD [6]. Influence of the
GRS on the disease outcome was examined with gener-
alized linear model in R version 3.4.3 [46]. The influence
of sex, age, and APOE genotype on the model was exam-
ined separately due to small number of samples. Pack-
ages lmtest [47], multiwayvcov [48], and fmsb [49] were
utilized in the model and in calculation of Nagelkerke’s
R square.
Reduced representation bisulfite sequencing and data
analysis
The libraries for RRBS were prepared as previously de-
scribed [50, 51] and were sequenced (1 × 50bp) with Illu-
mina HiSeq2500/3000. The trimmed reads (Trim Galore
v0.4.1 [52] were mapped to hg19 (blood) or hg38 (brain)
reference genome using Bismark v0.14.5/0.15.0 [53]. The
differentially methylated sites in blood were identified
using a paired comparison with RADMeth [54] using
CpG sites with coverage ≥ 10× in both twins in a pair,
and at least four pairs per study group, as an input. The
genomic inflation factors and bias caused by unobserved
factors were calculated and corrected with BACON
v1.10.1 package [55]. The genomic inflation factor was
1.07 (bias 0.30) for MZ and 1.14 (bias 0.50) for DZ
twins. We expect this step to correct for any bias caused
by cell type heterogeneity. The differentially methylated
regions were filtered according to Benjamin-Hochberg
false discovery rate adjusted p value combined with
RADMeth algorithm (< 0.05) followed by absolute aver-
age within-pair methylation difference (≥ 15.0%) and
central interval (70% interval < 0 or 70% interval > 0) for
these sites. Due to small cohort size, the analysis was not
adjusted for smoking. Information of the smoking his-
tory of the twin pairs is provided in the Additional file 9.
The effect sizes of the top-ranked differentially methyl-
ated sites from the monozygotic twin pairs (“discovery
set”) were examined for reproducibility in the dizygotic
twin pairs (“validation set”) by comparing the corre-
sponding values in a scatterplot. The effect size was
measured as methylation difference (% estimate by RAD-
Meth) and the standardized effect size was measured as
estimated methylation difference over standard deviation
of pairwise methylation. Also, for brain samples, the
CpG sites with coverage ≥ 10× and less than 99.9th per-
centile of coverage in each sample were included.
Methylkit v.1.1.7 [56] was used to detect differentially
methylated CpG sites with a minimum and consistent
difference of 15% and q value ≤ 0.05 as a cutoff.
MethylKit uses the SLIM method to adjust p values to q
values. The bisulfite conversion efficiency of all the sam-
ples was above 99% according to the lambda spike-in
control.
Targeted bisulfite pyrosequencing analysis
The PCR primers 5′-gtaatttagtggtgttgttgaat-3′, 5′-bio-
tin-cctaacccccaaccaacttcttactac-3′ and the sequencing
primer 5′-gggttgagttaagtgtgtttggtaga-3′ for the region
chr10:1405336-1405409 (hg19) were designed with Qia-
gen PyroMark AssayDesign SW 2.0. The samples were
prepared with Qiagen EpiTect Fast Bisulfite Conversion
and Qiagen PyroMark PCR kits and sequenced with
Qiagen PyroMark Q24 Advanced system. The amplicons
were analyzed with PyroMark Q24 Advanced software
version 3.0.0. The statistical analysis was carried in R
v3.4.3 [46] using packages lme4 v1.1-15 [20], car v2.1-6
[57], survival 2.42-4 [58], coxme 2.2-10 [59], and ggplot2
v2.2.1 [60]. Association of AD with CpG methylation
was examined with lme4 package, with modeling methy-
lation level as a function of disease status. Influence of
covariates and their interaction with AD in the model
was examined, including gender, age, zygosity, APOE
genotype, and smoking (never, ever) as fixed effects and
twin pair nested with genomic position and country of
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origin as random effects as specified in the results. The
model with the lowest AIC was chosen. The Cox mixed
effects model with coxme package was utilized to exam-
ine CpG methylation level as a prognostic marker of dis-
ease outcome. In this model, only age and gender were
included as fixed effects and twin pair information
nested with genomic position as a random effect.
Single-cell transcriptome analysis
PBMCs were isolated from the BD Vacutainer® CPT™
Cell Preparation tubes. Single-cell RNA sequencing
(scRNA-seq) libraries were prepared using ChromiumTM
controller, Single Cell 3′ Reagents kit (10x Genomics),
targeting at the recovery of 3000 cells per sample, and
were sequenced with Hiseq2500. The data was prepro-
cessed using Cell Ranger v. 1.2.0 (10x Genomics) and
the GRCh38 genome reference. The filtered gene-bar-
code unique molecular identifier count matrix of the ag-
gregated sample (Cell Ranger aggr tool) was normalized
using a global-scaling normalization from the Seurat R
package v. 1.4.0.9 [61]. Finally, the full Seurat scRNA-
seq analysis was performed for each sample individually.
Cells with unique gene count over 1750 or proportion of
mitochondrial genes over 10% were first filtered out.
Ten most significant principal components were selected
for the graph-based clustering, the different PBMC cell
types were identified using canonical markers, and the
cell type frequencies were estimated. Paired t test was
used to test differential expression between sample
groups.
Public data used
The data from GSE63061 [19] available at NCBI GEO
database was analyzed with GEO2R using default set-
tings [62, 63].
Additional files
Additional file 1: Table of APOE genotypes of the study individuals.
(XLSX 10 kb)
Additional file 2: Table of differentially methylated sites associated with
Alzheimer’s disease. Differentially methylated sites in Alzheimer’s disease
discordant a) monozygotic, b) dizygotic and in c) both twin pair groups
and d) in brain of non-twin subjects with Alzheimer’s disease in
comparison to reference subjects. (XLSX 415 kb)
Additional file 3: The effect sizes of the top-ranked differentially
methylated sites. The effect sizes of the top-ranked differentially
methylated sites from the monozygotic twin pairs (MZ, "Discovery set")
were examined for reproducibility in the dizygotic twin pairs ("DZ,
Validation set") by comparing the corresponding values in a scatterplot.
A) effect size was measured as methylation difference (% estimate by
RADMeth) and b) standardised effect size was measured as estimated
methylation difference over standard deviation of pairwise methylation
difference (n = 172, R = 0.452, p value = 4.754e-10 and R = 0.354, p value =
1.837e-6, respectively, by Pearson correlation test). The top 200 sites in
the MZ cohort were initially selected (ranked by q value) of which 172
met the coverage criteria for the DZ cohort. The correlation tests indicate
overall consistency in direction of methylation of the top-ranked MZ sites
in the DZ cohort. (TIF 4938 kb)
Additional file 4: Correlation of the DNA methylation in blood and
brain. Correlation of two peripheral blood DNA methylation marks
associated Alzheimer’s disease was examined in publicly available
Illumina 450K data available from blood and different regions of brain by
using the online tool: https://epigenetics.essex.ac.uk/bloodbrain/. (PDF
1782 kb)
Additional file 5: Gene expression level of candidate genes in blood of
non-twin subjects with Alzheimer’s disease in comparison to reference
subjects. Gene expression levels of the candidate genes from Additional
file 2c in GEO NCBI data from blood (GSE63061) of non-twin subjects
with Alzheimer’s disease in comparison to reference subjects. (XLSX 12
kb)
Additional file 6: Proportion of peripheral blood mononuclear cell
subtypes in twin pairs discordant for episodic memory as determined by
single cell 3' RNA-sequencing. (PDF 4 kb)
Additional file 7: Expression levels of the candidate genes in the
peripheral blood mononuclear cell subtypes in twin pairs discordant for
episodic memory as determined by single cell 3' RNA-sequencing. (TIF
37322 kb)
Additional file 8: Residual plots for linear mixed effects models. CpG
methylation of the region chr10:1,405,405-366, in exon three of ADARB2
gene was analyzed with targeted pyrosequencing. Association of disease
status with methylation level (outcome) was examined with linear mixed
effects model (lme4 R package) including zygosity, age and gender as
fixed effects and twin pair information nested with genomic position as
random effects. In the Figure is the representative data of the residual
plots for the models: a) me ~ dis + zyg + age + sex + dis * zyg + dis *
age + dis * sex + (1 | pairid/pos) in the data including both male and
female twin pairs, b) me ~ dis + zyg + age + dis * zyg + dis * age + (1 |
pairid/pos) in the data including only males. me = CpG methylation level,
dis = disease status, zyg = zygosity, pairid = twin pair information, pos =
genomic position. (JPG 297 kb)
Additional file 9: DNA methylation level of the ADARB2 mark is higher
in the Alzheimer’s disease cases with a history of smoking. Smoking
history was included in the linear mixed effects model as a fixed effect,
and interaction term, to determine whether this adjustment attenuates
association of the ADARB2 DNA methylation mark with Alzheimer’s
disease. The analysis was carried out by including all the 60 twin pairs
with smoking data available. According to the results the disease
association remained significant also when smoking was included in the
model (estimate 64.51%, SE 9.23, Wald t value 6.99, not adjusted for APOE
genotype). Smoking did interact with the disease status (estimate 8.10%,
SE 1.43, Wald t value 5.68) and the median methylation level was
increased in the cases with a smoking history in comparison to non-
smoking cases and controls as well as controls with a smoking history.
The association remained significant also when APOE genotype was
included in the model (estimate 35.41%, SE 9.41 and Wald t value 3.76).
A) DNA methylation levels for the ADARB2 mark in non-smokers and past
or current smokers are shown separately for females with APOE ε33
genotype who differ from the other groups and show no disease
association. B) Residual plot for the full model: me ~ dis + dis * zyg + dis *
age + dis * sex + dis * smo + dis * apoe + (1 | pairid/pos). me = CpG
methylation level, dis = disease status, zyg = zygosity, smo = smoking
history (never, ever), apoe = apoe genotype group, pairid = twin pair
information, pos = genomic position. (PDF 715 kb)
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